

REMARKS

I. Response to Restriction Requirement

In response to the restriction requirement mailed on August 13, 2003, applicant elect Group III, claims 1, 7-10 and 18-20, with traverse. The basis of the traversal is that numerous dependent claims are not properly restricted as they merely add elements to the elected invention of Class I + Class II antigens or other alloantigens. For example, claims 11-13 add viral antigens, claims 14 and 15 add cytokines, and claims 16 and 17 add costimulatory molecules.¹ If claim 1 is found allowable without reliance on the content of these claims, then the additional limitations set forth in claims 11-17 will not even come into play. Therefore, applicants respectfully submit that withdrawal of these claims is premature in light of the perceived allowability of claim 1.

II. Support for Amendments


Amendments to the claims and new claims are supported generally throughout the application, but in particular, support may be derived as follows: claim 1 – page 26, lines 16-17; claim 14 – page 31, line 10; claim 32 – page 26, lines 20-21; claim 33 – page 32, lines 20-21; claim 34 – page 29, lines 14-20; claim 35 – page 31, lines 8-9; claim 36 – page 31, lines 12-15. Thus, no new matter is presented by the amended/new claims.

¹ New claims 35 and 35 add immunostimulatory compounds, and are therefore presumed to be outside the scope of the initial restriction as well.

III. Conclusion

Applicants respectfully request entry of the amendments and examination of the claims as set forth in §I, above. Should the examiner have any questions regarding this submission, a telephone call to the undersigned is invited.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 22, 2004